Peter Thuss-Patience, Anica Högner, Eray Goekkurt, Michael Stahl, Albrecht Kretzschmar, Thorsten Götze, Gertraud Stocker, Peter Reichardt, Frank Kullmann, Daniel Pink, Prisca Bartels, Armin Jarosch, Axel Hinke, Christoph Schultheiß, Lisa Paschold, Alexander Stein, Mascha Binder
IMPORTANCE: Adding immune checkpoint inhibitors to chemotherapy has been associated with improved outcomes in metastatic esophagogastric adenocarcinoma, but treatment combinations and optimal patient selection need to be established. OBJECTIVE: To investigate the efficacy and tolerability of the programmed cell death ligand 1 (PDL-1) inhibitor avelumab with paclitaxel plus ramucirumab. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, single-group, phase 2 nonrandomized controlled trial was conducted among patients with second-line metastatic esophagogastric adenocarcinoma...
January 2, 2024: JAMA Network Open